SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2170546

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2170546

U.S. Flexible Endoscopic Surgery Robot Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 194 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 2550
PDF & Excel (Multi User License)
USD 3750
PDF & Excel (Enterprise User License)
USD 5050

Add to Cart

The U.S. Flexible Endoscopic Surgery Robot Market exceeded USD 609.8 million in 2025 and is projected to grow at 11.9% CAGR to reach USD 1.85 billion by 2035. Commercial development increasingly reflects procedure utilization, instrument replenishment, and service relationships within an installed platform base. Cleared bronchoscopy systems provide the established foundation, while urology and gastrointestinal applications broaden development opportunities. Providers assess navigation, imaging, training, and workflow support together. Suppliers must connect equipment placement with practical clinical use and recurring procedural requirements. This makes the quality of implementation and continuing institutional relationships important to revenue development beyond the initial purchase of a robotic platform.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$609.8 Million
Forecast Value$1.85 Billion
CAGR11.9%

Lung cancer screening creates a continuing pipeline of peripheral lesions requiring diagnostic assessment, supporting demand for robotic bronchoscopy workflows. High-volume providers seek dependable access, navigation, and confirmation within standardized procedures. Expansion of suitable ambulatory care creates another route to adoption beyond hospital-only purchasing, particularly for compact systems and disposable components. Commercial uptake depends on payment structures that recognize the associated equipment and operating costs. AI-enabled guidance also strengthens demand for integrated planning, image registration, and procedural data. These drivers favor systems that can fit institutional protocols and training, encouraging suppliers to coordinate hardware, software, and clinical support within a useful operating proposition.

Based on category, therapeutic applications generated USD 396.4 million in 2025. Their commercial significance includes recurring instrument use and provider requirements for controlled access during complex endoluminal interventions. Bronchoscopy provides an established platform for demand, while gastrointestinal applications may develop as regulatory and payment conditions permit. Suppliers must support repeat procedures as well as capital placement, connecting instruments and service with the platform's operating role. The segment therefore links equipment procurement with continuing consumption within clinical programs. Commercial performance depends on practical procedural use, making training, navigation, and support relevant to the relationship between an installed system and its contribution to provider workflows.

Within applications, urology is projected to generate USD 647.5 million by 2035. Dedicated robotic ureteroscopy systems could broaden a field in which conventional flexible procedures remain established. Product availability would expand competitive scope beyond bronchoscopy and create new requirements for clinician training and institutional assessment. Adoption depends on procedure economics and evidence of practical workflow benefits in urinary-tract and stone interventions. Suppliers must demonstrate usefulness within the setting where clinicians will operate the equipment. The segment's opportunity therefore rests on matching a dedicated platform with clinical routines and supporting implementation, rather than assume that access to robotics alone will determine procurement and ongoing utilization.

Intuitive Surgical accounted for approximately 58% of U.S. revenue in 2025. Its Ion platform benefits from established commercial resources, hospital relationships, and training infrastructure. As the platform matures, competitive strength increasingly depends on productive use across the installed base. Continuing procedures support instrument demand and reinforce the importance of clinical implementation. The company can draw on its existing institutional relationships to connect equipment placement with training and ongoing support. This positioning reflects the market's movement toward recurring procedural activity, giving operational engagement and platform utilization substantial commercial importance alongside opportunities to place additional systems within provider facilities.

Some of the major players in this market are Johnson and Johnson/Auris Health, Noah Medical, and Avicenna. Established competitors emphasize integrated navigation, imaging, and training, while alternative platforms pursue compact design and disposable instruments. Urology development could create a broader application portfolio for suppliers able to secure access and demonstrate practical advantages. Avicenna's dedicated ureteroscopy offering represents a development pathway whose U.S. participation depends on regulatory clearance. Competitive outcomes increasingly reflect the ability to convert technical capability into durable provider use. Clinical education, procedure economics, deployment complexity, and support for institutional workflows all influence selection. Suppliers must establish an effective operating relationship with providers to sustain adoption beyond initial procedural experience and compete with incumbent installed-base networks.

Product Code: 15183

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research Approach
  • 1.2 Quality Commitments
    • 1.2.1 GMI AI Policy & Data Integrity Commitment
      • 1.2.1.1 Source Consistency Protocol
  • 1.3 Research Trail & Confidence Scoring
    • 1.3.1 Research Trail Components
    • 1.3.2 Scoring Components
  • 1.4 Data Collection
    • 1.4.1 Partial List of Primary Sources
  • 1.5 Data Mining Sources
    • 1.5.1 Paid Sources
      • 1.5.1.1 Sources, by Region
  • 1.6 Base Estimates and Calculations
    • 1.6.1 Base Year Calculation
  • 1.7 Forecast Model
    • 1.7.1 Quantified Market Impact Analysis
      • 1.7.1.1 Mathematical Impact of Growth Parameters on Forecast
  • 1.8 Research Transparency Addendum
    • 1.8.1 Source Attribution Framework
    • 1.8.2 Quality Assurance Metrics
    • 1.8.3 Our Commitment to Trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° Synopsis
  • 2.2 Key Market Trends
    • 2.2.1 Category Trends
    • 2.2.2 Application Trends
    • 2.2.3 End Use Trends
  • 2.3 TAM Analysis, 2027-2035
  • 2.4 CXO Perspectives: Strategic Imperatives

Chapter 3. Industry Insights

  • 3.1 Industry Ecosystem Analysis
    • 3.1.1 Supplier Landscape
    • 3.1.2 Profit Margin
    • 3.1.3 Cost Structure
    • 3.1.4 Value Addition at Each Stage
    • 3.1.5 Factors Affecting the Value Chain
    • 3.1.6 Disruptions
  • 3.2 Industry Impact Forces
    • 3.2.1 Growth Drivers
      • 3.2.1.1 Growing Preference for Minimally Invasive Procedures in U.S. Healthcare Settings
      • 3.2.1.2 Advancements in Robotic Technology & Miniaturization
      • 3.2.1.3 Rising Prevalence of Chronic Diseases Requiring Endoscopic Intervention in the U.S.
      • 3.2.1.4 Integration of Artificial Intelligence (AI) in Surgical Robotics
    • 3.2.2 Industry Pitfalls and Challenges
      • 3.2.2.1 High Initial Investment & System Acquisition Costs
      • 3.2.2.2 Limited Reimbursement Policies for Robotic Endoscopic Procedures Under Medicare & Medicaid
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Development of Single-Use Robotic Endoscopic Systems
      • 3.2.3.2 Advancements in AI & Machine Learning for Autonomous Surgical Navigation
  • 3.3 Growth Potential Analysis
  • 3.4 Pricing Analysis (Driven by Primary Research)
    • 3.4.1 Historical Price Trend Analysis (Driven by Primary Research)
    • 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus) (Driven by Primary Research)
  • 3.5 Regulatory Landscape (U.S.-Specific)
    • 3.5.1 FDA 510(k) & De Novo Clearance Framework for Surgical Robots
    • 3.5.2 FDA Breakthrough Device Designation - Impact on Robotic Endoscopy Approvals
    • 3.5.3 CMS Reimbursement & CPT Code Coverage for Robotic Endoscopic Procedures
    • 3.5.4 HIPAA & Cybersecurity Requirements for AI-Integrated Surgical Systems
  • 3.6 Porter's Analysis
  • 3.7 PESTEL Analysis
  • 3.8 Trade Data Analysis (Based on Paid Database)
    • 3.8.1 Import/Export Volume & Value Trends
    • 3.8.2 Key Trade Corridors & Tariff Impact on U.S. Market Supply
  • 3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
    • 3.9.1 AI-Driven Disruption of Existing Business Models
    • 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
    • 3.9.3 Risks, Limitations & Regulatory Considerations
  • 3.10 Patent / IP Landscape
  • 3.11 Medical Infrastructure Landscape
  • 3.12 Epidemiology / Disease Burden

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company Market Share Analysis
    • 4.2.1 Market Concentration Analysis
  • 4.3 Competitive Analysis of Major Market Players
  • 4.4 Competitive Positioning Matrix
  • 4.5 Key Developments
    • 4.5.1 Mergers & Acquisitions
    • 4.5.2 Partnerships & Collaborations
    • 4.5.3 New Product Launches
    • 4.5.4 Expansion Plans and Funding
  • 4.6 Company Tier Benchmarking
    • 4.6.1 Tier Classification Criteria & Qualifying Thresholds
    • 4.6.2 Tier Positioning Matrix by Revenue, Geography & Innovation

Chapter 5. Market Estimates and Forecast, By Category, 2022-2035 (USD Million, Units)

  • 5.1 Key Trends
  • 5.2 Therapeutic
  • 5.3 Diagnostic
  • 5.4 Forecast Assumptions & Scenario Analysis (Driven by Primary Research)
    • 5.4.1 Base Case - Key Macro & Industry Variables Driving CAGR
    • 5.4.2 Bull Scenario - Upside Assumptions & Trigger Conditions
    • 5.4.3 Bear Scenario - Downside Assumptions & Risk Factors
    • 5.4.4 Sensitivity Analysis - Variables the Forecast is Most Sensitive To

Chapter 6. Market Estimates and Forecast, By Application, 2022-2035 (USD Million, Units)

  • 6.1 Key Trends
  • 6.2 Urology
  • 6.3 Respiratory Applications
  • 6.4 Gastrointestinal Applications
  • 6.5 Other Applications
  • 6.6 Forecast Assumptions & Scenario Analysis (Driven by Primary Research)
    • 6.6.1 Base Case - Key Macro & Industry Variables Driving CAGR
    • 6.6.2 Bull Scenario - Upside Assumptions & Trigger Conditions
    • 6.6.3 Bear Scenario - Downside Assumptions & Risk Factors
    • 6.6.4 Sensitivity Analysis - Variables the Forecast is Most Sensitive To

Chapter 7. Market Estimates and Forecast, By End Use, 2022-2035 (USD Million, Units)

  • 7.1 Key Trends
  • 7.2 Hospitals & Clinics
  • 7.3 Ambulatory Surgical Centers
  • 7.4 Other End Uses
  • 7.5 Forecast Assumptions & Scenario Analysis (Driven by Primary Research)
    • 7.5.1 Base Case - Key Macro & Industry Variables Driving CAGR
    • 7.5.2 Bull Scenario - Upside Assumptions & Trigger Conditions
    • 7.5.3 Bear Scenario - Downside Assumptions & Risk Factors
    • 7.5.4 Sensitivity Analysis - Variables the Forecast is Most Sensitive To

Chapter 8. Company Profiles

  • 8.1 Intuitive Surgical
  • 8.2 Johnson & Johnson / Auris Health
  • 8.3 Noah Medical (Galaxy)
  • 8.4 Avicenna
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!